StockNews.AI
MLTX
StockNews.AI
12 hrs

MOONLAKE ALERT: Bragar Eagel & Squire, P.C. Announces Investigation into MoonLake Immunotherapeutics on Behalf of MoonLake Stockholders and Encourages Investors to Contact the Firm

1. Bragar Eagel & Squire is investigating potential claims against MLTX. 2. MLTX stock fell 89.9% following trial results indicating failure. 3. Investors who lost money are encouraged to contact the law firm. 4. The firm claims potential violations of federal securities laws by MLTX. 5. Legal actions may intensify investor uncertainty around MLTX.

4m saved
Insight
Article

FAQ

Why Very Bearish?

MLTX’s recent stock plummet of 89.9% indicates severe investor loss and distrust. Companies historically face long recoveries post such dramatic declines.

How important is it?

The severe drop and legal scrutiny signify material impact on MLTX's future. Investor confidence is likely to be severely shaken.

Why Short Term?

The immediate fallout from legal investigations can lead to further price depressions. Short-term reactions include selling pressure as uncertainty looms.

Related Companies

BRKRREGNAMGN
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In MoonLake (MLTX) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Moon Lake and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ:MLTX) on behalf of MoonLake stockholders. Our investigation concerns whether MoonLake has violated the federal securities laws and/or engaged in other unlawful business practices. Investigation Details: On September 29, 2025, before the market opened, MoonLake Immunotherapeutics filed with the SEC a current report on Form 8-K. Attached to the current report was a press release which stated that, in MoonLake’s VELA-2 trial, “intercurrent events in the higher-than-expected placebo arm precluded the study from achieving statistical significance in the week 16 primary endpoint using the composite strategy[.]”On this news, MoonLake stock plummeted 89.9% on September 29, 2025. Next Steps: If you purchased or otherwise acquired MoonLake shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

Related News